Novartis

News

Reuters - 2 days ago

Companies ask US judiciary group to force lawsuit funding disclosures

UPDATE 1-Companies ask US judiciary group to force lawsuit funding disclosures Adds comment in paragraphs 11, 12 from funding advocate By Mike Scarcella Oct 3 (Reuters) - More than 100 major companies from the technology, pharmaceutical, automotive and other sectors have urged the U.S. judiciary to adopt a nationwide rule requiring disclosure of third-party litigation funding in lawsuits.

Reuters - 2 days ago

Companies ask US judiciary group to force lawsuit funding disclosures

Reuters - 2 days ago

Companies ask US judiciary group to force lawsuit funding disclosures

Companies ask US judiciary group to force lawsuit funding disclosures By Mike Scarcella Oct 3 (Reuters) - More than 100 major companies from the technology, pharmaceutical, automotive and other sectors have urged the U.S. judiciary to adopt a nationwide rule requiring disclosure of third-party litigation funding in lawsuits. Companies including Amazon.com, Google, Cisco, Meta, Comcast, Exxon, Zurich, Eli Lilly, Bayer, Ford, Pfizer and Novartis submitted the letter on Wednesday to the federal cou

Reuters - 2 days ago

US office real estate market shows signs of bottoming after big discount sales

ANALYSIS-US office real estate market shows signs of bottoming after big discount sales Prices for office buildings fell 12.4% year-over-year as of Q2 Sales of stressed properties at big discounts set new pricing benchmarks Federal Reserve's rate cuts may not be enough to revive market Adds refinancing stats in paragraph 16, updates headline By Matt Tracy and Shankar Ramakrishnan Oct 3 (Reuters) - The beleaguered U.S.

Reuters - 2 days ago

US office market shows signs of bottoming after big discount sales

ANALYSIS-US office market shows signs of bottoming after big discount sales Prices for office buildings fell 12.4% year-over-year as of Q2 Sales of stressed properties at big discounts set new pricing benchmarks Federal Reserve's rate cuts may not be enough to revive market By Matt Tracy and Shankar Ramakrishnan Oct 3 (Reuters) - The beleaguered U.S.

Reuters - 2 days ago

Swiss stocks - Factors to watch on October 3

Swiss stocks - Factors to watch on October 3 ZURICH/GDANSK, Oct 3(Reuters) - Here are some of the main factors that may affect Swiss stocks on Thursday: COMPANY STATEMENTS Sika AG SIKA.S holds its Capital Markets Day. ANALYSTS' VIEWS NOVARTIS AG NOVN.S - JEFFERIES RAISES TARGET PRICE TO $124 FROM $123 ECONOMY Swiss September inflation data due at 0630 GMT.

Reuters - 1 week ago

Why gene therapy for sickle cell is slow to catch on with patients

INSIGHT-Why gene therapy for sickle cell is slow to catch on with patients By Deena Beasley LOS ANGELES, Sept 28 (Reuters) - Student Zoe Davis, 20, was just weeks into her junior year when she landed back in the hospital with severe sickle cell pain earlier this month. She is doing what she can to prevent the crippling attacks in her arms, legs and abdomen that are becoming more frequent.

Reuters - 1 week ago

Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say

UPDATE 1-Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say EMA raises concerns about deaths in Oxbryta trials Shares of Agios and Fulcrum rise after Pfizer's decision Adds FDA statement in paragraph 4 By Kashish Tandon and Christy Santhosh Sept 26 (Reuters) - Pfizer's PFE.N decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said.

Reuters - 1 week ago

Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say

Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say EMA raises concerns about deaths in Oxbryta trials Shares of Agios and Fulcrum rise after Pfizer's decision By Kashish Tandon and Christy Santhosh Sept 26 (Reuters) - Pfizer's PFE.N decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said.

Reuters - 2 weeks ago

Generate:Biomedicines Announces Multi-Target Collaboration With Novartis To Discover & Develop Protein Therapeutics With Generative Ai

BRIEF-Generate:Biomedicines Announces Multi-Target Collaboration With Novartis To Discover & Develop Protein Therapeutics With Generative Ai Sept 24 (Reuters) - Novartis AG NOVN.S : GENERATE:BIOMEDICINES: ANNOUNCES MULTI-TARGET COLLABORATION WITH NOVARTIS TO DISCOVER & DEVELOP PROTEIN THERAPEUTICS WITH GENERATIVE AI GENERATE:BIOMEDICINES - POTENTIA

Reuters - 2 weeks ago

Sanofi's tolebrutinib drug delays progressive MS by 31% in trial

UPDATE 1-Sanofi's tolebrutinib drug delays progressive MS by 31% in trial Adds details and background throughout By Ludwig Burger FRANKFURT, Sept 20 (Reuters) - Sanofi SASY.PA said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later this year.

Reuters - 2 weeks ago

Swiss trade surplus at CHF 4.578 bln in August

TABLE-Swiss trade surplus at CHF 4.578 bln in August Sept 19 (Reuters) - Switzerland ran a merchandise trade surplus of 4.578 billion Swiss francs in August, the Federal Customs Office said on Thursday. KEY FIGURES (millions of Swiss francs) August 2024 July 2024 Imports 15.912 19.215 Exports 20.491 24.092 Balance 4.578 4.877 The figures exclude precious metals and stones, works of art and antiques.

Reuters - 2 weeks ago

Vontobel assesses obesity drugs impact for Swiss insurers, med-tech companies

BUZZ-Vontobel assesses obesity drugs impact for Swiss insurers, med-tech companies ** Vontobel estimates the market potential for obesity drugs in the U.S. to reach a three-digit billion U.S. dollar amount and picks Swiss Re SRENH.S and Ypsomed YPSN.S as the most likely to profit from it ** Among Swiss life insurers, Swiss Re could benefit the most from a rising demand in life and health reinsurance, with a market share of about 15%, as obesity drugs improve life expectancy, it says ** Its posit

Reuters - 2 weeks ago

Novartis: New Data In Relapsing MS Reinforce Benefits Of Kesimpta For First-Line And Switch Patients

BRIEF-Novartis: New Data In Relapsing MS Reinforce Benefits Of Kesimpta For First-Line And Switch Patients Sept 18 (Reuters) - Novartis AG NOVN.S : NEW NOVARTIS DATA IN RELAPSING MS REINFORCE BENEFITS OF KESIMPTA® FOR FIRST-LINE AND SWITCH PATIENTS NEARLY 90% OF FIRST-LINE KESIMPTA PATIENTS HAD NO DISABILITY PROGRESSION INDEPENDENT OF RELAPSE ACTI

Reuters - 2 weeks ago

Swiss stocks - Factors to watch on September 18

Swiss stocks - Factors to watch on September 18 ZURICH/GDANSK, Sept 18 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Wednesday: MEYER BURGER TECHNOLOGY AG MBTN.S The company said it has planned the streamlining of its group structure and the reduction of its workforce. NOVARTIS AG NOVN.S FDA approves Kisqali to reduce risk of recurrence in people with HR+/HER2- early breast cancer.

Reuters - 3 weeks ago

Novartis Says FDA Approves Kisqali To Reduce Risk Of Recurrence In People With HR+/Early Breast Cancer

BRIEF-Novartis Says FDA Approves Kisqali To Reduce Risk Of Recurrence In People With HR+/HER2- Early Breast Cancer Sept 17 (Reuters) - Novartis AG NOVN.S : FDA APPROVES NOVARTIS KISQALI® TO REDUCE RISK OF RECURRENCE IN PEOPLE WITH HR+/HER2- EARLY BREAST CANCER Source text for Eikon: ID:nGNEVXqGz Further company coverage: NOVN.S

Reuters - 3 weeks ago

Novartis Novartis Kisqali® Shows Deepening Benefit In New Analysis, Reducing Risk Of Recurrence By 28.5% In A Broad Population Of Patients With Early Breast Cancer

BRIEF-Novartis Novartis Kisqali® Shows Deepening Benefit In New Analysis, Reducing Risk Of Recurrence By 28.5% In A Broad Population Of Patients With Early Breast Cancer Novartis AG NOVN.S : : NOVARTIS KISQALI® SHOWS DEEPENING BENEFIT IN NEW ANALYSIS, REDUCING RISK OF RECURRENCE BY 28.5% IN A BROAD POPULATION OF PATIENTS WITH EARLY BREAST CANCER

Reuters - 3 weeks ago

US FDA approves injectable version of Roche's multiple sclerosis therapy

UPDATE 1-US FDA approves injectable version of Roche's multiple sclerosis therapy Adds price and availability in paragraph 4 Sept 13 (Reuters) - The U.S. Food and Drug Administration on Friday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The subcutaneous or under-the-skin therapy called Ocrevus Zunovo has the potential to expand treatment options to centers unable to administer the IV version.

Reuters - 3 weeks ago

US FDA approves injectable version of Roche's multiple sclerosis therapy

US FDA approves injectable version of Roche's multiple sclerosis therapy Sept 13 (Reuters) - The U.S. Food and Drug Administration on Friday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The subcutaneous or under-the-skin therapy called Ocrevus Zunovo has the potential to expand treatment options to centers unable to administer the IV version.

Reuters - 3 weeks ago

US FDA approves injectable version of Roche's multiple sclerosis therapy

UPDATE 1-US FDA approves injectable version of Roche's multiple sclerosis therapy Adds background throughout Sept 12 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The therapy is already approved as an infusion or IV therapy for multiple sclerosis, which is given twice a year, under the brand name Ocrevus.

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Novartis

News

Conditions

Popular Assets

XM Live Chat